Temasek pumping US$800 million into Alphabet's medical unit
It will get minority stake and board seat in Verily; deal will help latter expand into China
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
San Francisco
ALPHABET Inc's medical arm, Verily Life Sciences LLC, is getting a major influx of cash from a Singapore investment company, boosting the odds of taking their futuristic approach to healthcare into Asian markets.
Temasek Holdings Pte Ltd, with US$415.8 billion in assets, is investing US$800 million in Verily, according to a statement from the company on Thursday. In exchange, Temasek will get a minority stake in Verily and a seat on its operating board.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
